Hepato Cellular Carcinoma (HCC) Clinical Trials in Tianjin, Tianjin Municipality

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence